Clinical trials: Vaginitis Candida
Vaginal Infection, ASC-US
Probiotic Implementation as Help in Solving Vaginal Infections
Over recent years, a growing interest has developed in microbiota and in the concept of maintaining a special balance between Lactobacillus and other bacteria species in order to promote women's well-being.
- Trial name
- NCT03372395
- Testing
- Lactobacillus rhamnosus BMX 54
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Bacterial Vaginosis, Candida Vaginitis
Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis
In the clinical performance part of this study, prospectively acquired clinician-collected and clinician-instructed, self-collected vaginal swab specimens collected in cobas® PCR Media will be taken from a minimum of 500…
- Trial name
- NCT06975436
- Testing
- cobas® BV/CV test, BD Max™ Vaginal Panel, Cepheid Xpert Xpress MVP
- Where
- 10 sites in United States, Bulgaria and 1 more
- Volunteers
- 738 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Microbiome, Antibiotic-Induced VVC
Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women
Background: Vaginal yeast infections are caused by a fungus called Candida. Candida can live harmlessly in the vagina, but most women will have symptoms from a vaginal yeast infection at some point during their life.
- Conditions
- Microbiome, Antibiotic-Induced VVC, Vaginal Candidiasis
- Trial name
- NCT01915251
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Recurrent Vulvovaginal Candidiasis
Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection
Pevion Biotech develops a state-of-the-art vaccine against recurrent vulvovaginal candidiasis (RVVC) caused by the pathogenic form of Candida albicans especially in pre-menopausal women of childbearing age with a history of…
- Trial name
- NCT01067131
- Testing
- PEV7C1, PEV7C9, PEV7B2
- Where
- 2 sites in Switzerland
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pevion Biotech Ltd
Candidiasis, Vulvovaginal, Recurrent Candidiasis of Vagina
The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms
The aim of the study is to investigate the efficacy of Fluconazol versus L-Mesitran in the treatment of patients with recurrent vulvovaginal candidiasis. Vaginal swabs will be analyzed after 1, 6 and 12 months.
- Trial name
- NCT05367089
- Testing
- Fluconazole, L-Mesitran
- Where
- 2 sites in Netherlands
- Volunteers
- 252 people
- Sponsor
- Maastricht University Medical Center
Vulvovaginal Candidiasis
Comparative Performance of a Vaginal Yeast Test
The purpose of this study is to establish lay user performance criteria for the SavvyCheck Vaginal Yeast Test in comparison to standard vaginal yeast culture and identification method for Candida (the Reference Method).
- Trial name
- NCT05079711
- Testing
- SavvyCheck Vaginal Yeast Test (rapid, point-of-care diagnostic test)
- Where
- 3 sites in United States, Germany
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Uniformed Services University of the Health Sciences
Bacterial Vaginosis, Candida Vaginal
The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study
Three-quarters of women have bacterial vaginosis (BV) or vaginal thrush/candida yeast infection at least once during their lifetime. Symptoms can include abnormal vaginal discharge, soreness, itching and an unpleasant smell.
- Trial name
- LISA (NCT05434104)
- Testing
- Vaginal lactoferrin, Usual care
- Where
- 2 sites in United Kingdom
- Volunteers
- 114 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Vulvovaginal Candidiasis
Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis
The objectives of this study were to demonstrate comparable safety and efficacy of Terconazole Vaginal Suppositories, 80 mg(Test Product) and Terconazole Vaginal Suppositories, 80 mg(Reference Product) in the treatment of…
- Trial name
- NCT00803738
- Testing
- Terconazole Vaginal Suppository, Terazol Vaginal Suppository
- Volunteers
- 572 people
- Sponsor
- Padagis LLC
Candida Vulvovaginitis
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)
This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.
- Trial name
- NCT03734991
- Testing
- Ibrexafungerp
- Where
- 25 sites in United States
- Volunteers
- 376 people
- Sponsor
- Scynexis, Inc.
Vaginal Candidiasis
Prevention of Recurrent Vulvovaginal Candidiasis With Lactibiane Candisis 5M®
Vulvovaginal candidiasis (VVC) is a common infection among women that is associated with considerable morbidity and health-care cost. 75% of women will suffer of Candida infection for at least one time in their life.
- Trial name
- NCT00915629
- Testing
- Lactibiane candisis 5M
- Where
- France
- Volunteers
- 134 people
- Sponsor
- PiLeJe
Vaginal Diseases
Probiotic for Vaginal Candidiasis in Pregnant Women
This project aims to study the benefits of a probiotic product, STP4 for vaginal health properties, primarily prevention of vaginal candidiasis, among pregnant women in second and third trimester pregnancy.
- Trial name
- NCT03940612
- Testing
- STP4 (product with probiotics)
- Where
- Malaysia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Universiti Sains Malaysia
Candida Vulvovaginitis
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis
This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.
- Trial name
- Vanish 306 (NCT03987620)
- Testing
- Ibrexafungerp
- Where
- 41 sites in United States, Bulgaria
- Volunteers
- 455 people
- Sponsor
- Scynexis, Inc.
Bacterial Vaginosis, Vulvovaginal Candidiasis
Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection
The purpose of this clinical trial is to investigate the clinical efficacy and safety of a Live Biotherapeutic Product (BGY-1601-VT) intended as a first line of treatment in cases of acute vaginal infection without upfront…
- Trial name
- ELINA (NCT06450990)
- Testing
- BGY-1601-VT
- Volunteers
- 165 people
- Sponsor
- NEXBIOME THERAPEUTICS
Sexually Transmitted Infections (Not HIV or Hepatitis), Premature Birth
Genital Tract Infections, the Vaginal Microbiome and Gestational Age at Birth Among Pregnant Women in South Africa
This cohort study plans to investigate associations between the presence of multiple lower genital tract microorganisms in pregnancy and gestational age at birth.
- Conditions
- Sexually Transmitted Infections (Not HIV or Hepatitis), Premature Birth, Pregnancy; Infection, Microbial Colonization
- Trial name
- NCT06131749
- Testing
- No intervention
- Where
- South Africa
- Volunteers
- 603 people
- Sponsor
- University of Bern
Bacterial Vaginosis, Candidosis Vaginal
Lacticaseibacillus Rhamnosus CA15 (DSM 33960) Strain as a New Driver in Restoring the Normal Vaginal Microbiota
The aim of the present randomized double-blind placebo-controlled trial is to evaluate the efficacy of a probiotic formulation, containing the probiotic strain Lacticaseibacillus rhamnosus CA15 (DSM 33960), in the treatment of…
- Conditions
- Bacterial Vaginosis, Candidosis Vaginal, Urinary Tract Infections
- Trial name
- NCT05796921
- Testing
- Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain
- Where
- Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Agnese Maria Chiara Rapisarda
Vaginal Infection, Candidiasis
Investigation of the Relationship Between Salivary Histatine-5 Level and Vaginal Candidiasis in Women
The low Histatine-5 (HST-5) level of the saliva can lead to vaginal candidiasis. Because HST-5 level in the saliva can effect vaginal Ph, flora and local defence mechanisms.
- Trial name
- NCT05044156
- Testing
- salivary sample
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Usak State Hospital
Vulvovaginal Candidiasis (VVC), Yeast Vaginitis
Clinical Study of a Vaginal Cooling Device for the Treatment of Vulvovaginal Candidiasis (VVC)
The objective of this study is to determine clinical cure rate and safety of a proprietary Vaginal Cooling Device (VCD) in women with VCC.
- Trial name
- NCT06983041
- Testing
- vaginal cooling device
- Where
- 10 sites in United States
- Volunteers
- 55 people
- Sponsor
- Coologics, Inc
Vaginal Candidiasis, Bacterial Vaginosis
Observational Program Neo-Penotran® Forte
Vaginitis is the most common gynecologic diagnosis in the primary care setting. In approximately 90 percent of affected women, this condition occurs secondary to bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis or…
- Conditions
- Vaginal Candidiasis, Bacterial Vaginosis, Trichomonal Vaginitis
- Trial name
- NCT01335373
- Testing
- Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)
- Where
- Kazakhstan
- Volunteers
- 13,024 people
- Sponsor
- Bayer
Candidiasis, Vulvovaginal, Candidiasis of Vagina
Non-ablative Er:YAG for Recurrent Candidiasis
The objective of the study wa to assess the safety, acceptability and effectiveness of non-ablative Er:YAG laser therapy for treatment of symptoms and microbiological conditions of women with recurrent vulvovaginal candidiasis…
- Conditions
- Candidiasis, Vulvovaginal, Candidiasis of Vagina, Candidiasis, Genital, Recurrent Candidiasis of Vagina
- Trial name
- NCT06572488
- Testing
- Non-ablative SMOOTH mode Er:YAG laser
- Where
- Argentina
- Volunteers
- 167 people
- Sponsor
- Espacio Gaspar Clinic